iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa#China#Chengdu#retinitis_pigmentosa#iRegene_Therapeutics#NouvSight001
iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa
iRegene Therapeutics advances its cell therapy NouvSight001, cleared for clinical trials in the U.S. and China, targeting retinitis pigmentosa.
third-news.com
September 29, 2026 at 5:47 AM
iRegene's NouvSight001 Receives Clinical Trial Clearance in the U.S. and China for Retinitis Pigmentosa#China#Chengdu#retinitis_pigmentosa#iRegene_Therapeutics#NouvSight001
iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations#NouvNeu001#FDA_Designation#iRegene_Therapeutics
iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations
iRegene Therapeutics has received dual FDA recognitions for NouvNeu001—highlighting its potential to transform Parkinson's treatment with innovative cell therapy.
third-news.com
January 19, 2026 at 1:10 PM
iRegene's NouvNeu001 Becomes the First iPSC Therapy with Dual FDA Designations#NouvNeu001#FDA_Designation#iRegene_Therapeutics